TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06565195: A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

Sponsor: Prevail Therapeutics · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 124 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,583,040

Rescue Site Savings

+$1,055,360

Unlock Full NCT06565195 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06565195 Rescue Dossier →